Eli Lilly launches program to boost employer coverage of obesity drugs
CNBC • • general
Key Points:
- Eli Lilly has launched "Employer Connect," a new program aimed at helping more U.S. employers cover obesity drugs by offering greater flexibility and transparency in benefits design, addressing a major barrier to patient access.
- The program allows employers to pay a net discounted price of $449 per month for a multi-dose form of Lilly's weight loss drug Zepbound, significantly lower than the list price of over $1,000, without involving rebates.
- Employers can choose from over a dozen third-party administrators on Lilly's platform to manage obesity treatment benefits, tailoring services such as enrollment, claims, telehealth, and lifestyle support to their workforce needs.
- Currently, only about 20% of firms with more than 200 workers and 43% of
